nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Clonus—Vandetanib—thyroid cancer	0.0412	0.149	CcSEcCtD
Lithium—IMPA2—saliva-secreting gland—thyroid cancer	0.0218	0.119	CbGeAlD
Lithium—GSK3A—saliva-secreting gland—thyroid cancer	0.0186	0.101	CbGeAlD
Lithium—IMPA2—trachea—thyroid cancer	0.0169	0.0917	CbGeAlD
Lithium—IMPA1—head—thyroid cancer	0.0158	0.0857	CbGeAlD
Lithium—GSK3A—trachea—thyroid cancer	0.0144	0.0782	CbGeAlD
Lithium—GRIA3—head—thyroid cancer	0.0134	0.0729	CbGeAlD
Lithium—IMPA2—thyroid gland—thyroid cancer	0.0133	0.0725	CbGeAlD
Lithium—GSK3B—thyroid gland—thyroid cancer	0.0131	0.0712	CbGeAlD
Lithium—GSK3B—head—thyroid cancer	0.0116	0.0631	CbGeAlD
Lithium—GSK3A—thyroid gland—thyroid cancer	0.0114	0.0619	CbGeAlD
Lithium—GSK3A—head—thyroid cancer	0.0101	0.0549	CbGeAlD
Lithium—IMPA2—lymph node—thyroid cancer	0.00828	0.0451	CbGeAlD
Lithium—GSK3B—lymph node—thyroid cancer	0.00813	0.0442	CbGeAlD
Lithium—Hyperthyroidism—Sorafenib—thyroid cancer	0.00811	0.0293	CcSEcCtD
Lithium—Folliculitis—Vandetanib—thyroid cancer	0.00756	0.0273	CcSEcCtD
Lithium—Hypothyroidism—Vandetanib—thyroid cancer	0.0074	0.0267	CcSEcCtD
Lithium—GSK3A—lymph node—thyroid cancer	0.00707	0.0384	CbGeAlD
Lithium—Hypercalcaemia—Vandetanib—thyroid cancer	0.00684	0.0247	CcSEcCtD
Lithium—Skin ulcer—Vandetanib—thyroid cancer	0.0061	0.022	CcSEcCtD
Lithium—Folliculitis—Sorafenib—thyroid cancer	0.0051	0.0184	CcSEcCtD
Lithium—Hypothyroidism—Sorafenib—thyroid cancer	0.00499	0.018	CcSEcCtD
Lithium—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00459	0.0166	CcSEcCtD
Lithium—Lethargy—Vandetanib—thyroid cancer	0.00352	0.0127	CcSEcCtD
Lithium—Dehydration—Vandetanib—thyroid cancer	0.00321	0.0116	CcSEcCtD
Lithium—Dry skin—Vandetanib—thyroid cancer	0.00316	0.0114	CcSEcCtD
Lithium—Gastritis—Vandetanib—thyroid cancer	0.00305	0.011	CcSEcCtD
Lithium—Weight decreased—Vandetanib—thyroid cancer	0.0027	0.00973	CcSEcCtD
Lithium—Hyperglycaemia—Vandetanib—thyroid cancer	0.00269	0.0097	CcSEcCtD
Lithium—Bradycardia—Vandetanib—thyroid cancer	0.00243	0.00877	CcSEcCtD
Lithium—Dehydration—Sorafenib—thyroid cancer	0.00216	0.00781	CcSEcCtD
Lithium—Blindness—Epirubicin—thyroid cancer	0.00214	0.00772	CcSEcCtD
Lithium—Dry skin—Sorafenib—thyroid cancer	0.00213	0.0077	CcSEcCtD
Lithium—Arrhythmia—Vandetanib—thyroid cancer	0.00213	0.00769	CcSEcCtD
Lithium—Alopecia—Vandetanib—thyroid cancer	0.00211	0.00761	CcSEcCtD
Lithium—Gastritis—Sorafenib—thyroid cancer	0.00206	0.00743	CcSEcCtD
Lithium—Dysgeusia—Vandetanib—thyroid cancer	0.00203	0.00734	CcSEcCtD
Lithium—Blindness—Doxorubicin—thyroid cancer	0.00198	0.00714	CcSEcCtD
Lithium—Vision blurred—Vandetanib—thyroid cancer	0.00196	0.00706	CcSEcCtD
Lithium—Tremor—Vandetanib—thyroid cancer	0.00195	0.00702	CcSEcCtD
Lithium—Optic neuritis—Epirubicin—thyroid cancer	0.00193	0.00695	CcSEcCtD
Lithium—Folliculitis—Epirubicin—thyroid cancer	0.00188	0.0068	CcSEcCtD
Lithium—Psoriasis—Epirubicin—thyroid cancer	0.00188	0.0068	CcSEcCtD
Lithium—Erectile dysfunction—Sorafenib—thyroid cancer	0.00185	0.00668	CcSEcCtD
Lithium—Loss of consciousness—Vandetanib—thyroid cancer	0.00182	0.00659	CcSEcCtD
Lithium—Weight decreased—Sorafenib—thyroid cancer	0.00182	0.00657	CcSEcCtD
Lithium—Convulsion—Vandetanib—thyroid cancer	0.0018	0.00649	CcSEcCtD
Lithium—Optic neuritis—Doxorubicin—thyroid cancer	0.00178	0.00643	CcSEcCtD
Lithium—Arthralgia—Vandetanib—thyroid cancer	0.00177	0.00638	CcSEcCtD
Lithium—Psoriasis—Doxorubicin—thyroid cancer	0.00174	0.00629	CcSEcCtD
Lithium—Folliculitis—Doxorubicin—thyroid cancer	0.00174	0.00629	CcSEcCtD
Lithium—Dry mouth—Vandetanib—thyroid cancer	0.00173	0.00624	CcSEcCtD
Lithium—Hypercalcaemia—Epirubicin—thyroid cancer	0.0017	0.00615	CcSEcCtD
Lithium—Oedema—Vandetanib—thyroid cancer	0.00169	0.00612	CcSEcCtD
Lithium—Nystagmus—Epirubicin—thyroid cancer	0.00166	0.00598	CcSEcCtD
Lithium—Albuminuria—Epirubicin—thyroid cancer	0.00159	0.00573	CcSEcCtD
Lithium—Hypercalcaemia—Doxorubicin—thyroid cancer	0.00158	0.00569	CcSEcCtD
Lithium—Scotoma—Epirubicin—thyroid cancer	0.00156	0.00563	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00154	0.00557	CcSEcCtD
Lithium—Nystagmus—Doxorubicin—thyroid cancer	0.00153	0.00554	CcSEcCtD
Lithium—Skin ulcer—Epirubicin—thyroid cancer	0.00152	0.00549	CcSEcCtD
Lithium—Tinnitus—Sorafenib—thyroid cancer	0.0015	0.00542	CcSEcCtD
Lithium—Dyspepsia—Vandetanib—thyroid cancer	0.00149	0.00538	CcSEcCtD
Lithium—Decreased appetite—Vandetanib—thyroid cancer	0.00147	0.00532	CcSEcCtD
Lithium—Albuminuria—Doxorubicin—thyroid cancer	0.00147	0.0053	CcSEcCtD
Lithium—Glycosuria—Epirubicin—thyroid cancer	0.00146	0.00528	CcSEcCtD
Lithium—Fatigue—Vandetanib—thyroid cancer	0.00146	0.00527	CcSEcCtD
Lithium—Scotoma—Doxorubicin—thyroid cancer	0.00144	0.00521	CcSEcCtD
Lithium—Arrhythmia—Sorafenib—thyroid cancer	0.00144	0.00519	CcSEcCtD
Lithium—Alopecia—Sorafenib—thyroid cancer	0.00142	0.00513	CcSEcCtD
Lithium—Skin ulcer—Doxorubicin—thyroid cancer	0.00141	0.00508	CcSEcCtD
Lithium—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00139	0.005	CcSEcCtD
Lithium—Dysgeusia—Sorafenib—thyroid cancer	0.00137	0.00495	CcSEcCtD
Lithium—Glycosuria—Doxorubicin—thyroid cancer	0.00135	0.00488	CcSEcCtD
Lithium—Body temperature increased—Vandetanib—thyroid cancer	0.00134	0.00484	CcSEcCtD
Lithium—Abdominal pain—Vandetanib—thyroid cancer	0.00134	0.00484	CcSEcCtD
Lithium—Oliguria—Epirubicin—thyroid cancer	0.00128	0.00464	CcSEcCtD
Lithium—Angioedema—Sorafenib—thyroid cancer	0.00128	0.00462	CcSEcCtD
Lithium—Syncope—Sorafenib—thyroid cancer	0.00126	0.00453	CcSEcCtD
Lithium—Dysarthria—Epirubicin—thyroid cancer	0.00125	0.00452	CcSEcCtD
Lithium—Loss of consciousness—Sorafenib—thyroid cancer	0.00123	0.00444	CcSEcCtD
Lithium—Asthenia—Vandetanib—thyroid cancer	0.00122	0.00439	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—thyroid cancer	0.00121	0.00435	CcSEcCtD
Lithium—Arthralgia—Sorafenib—thyroid cancer	0.00119	0.0043	CcSEcCtD
Lithium—Oliguria—Doxorubicin—thyroid cancer	0.00119	0.00429	CcSEcCtD
Lithium—Dry mouth—Sorafenib—thyroid cancer	0.00117	0.00421	CcSEcCtD
Lithium—Diarrhoea—Vandetanib—thyroid cancer	0.00116	0.00419	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—thyroid cancer	0.00116	0.00418	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00115	0.00415	CcSEcCtD
Lithium—Shock—Sorafenib—thyroid cancer	0.00112	0.00406	CcSEcCtD
Lithium—Dizziness—Vandetanib—thyroid cancer	0.00112	0.00405	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—thyroid cancer	0.00112	0.00403	CcSEcCtD
Lithium—Anorexia—Sorafenib—thyroid cancer	0.00109	0.00393	CcSEcCtD
Lithium—Coma—Epirubicin—thyroid cancer	0.00108	0.00391	CcSEcCtD
Lithium—Vomiting—Vandetanib—thyroid cancer	0.00108	0.00389	CcSEcCtD
Lithium—Rash—Vandetanib—thyroid cancer	0.00107	0.00386	CcSEcCtD
Lithium—Dermatitis—Vandetanib—thyroid cancer	0.00107	0.00385	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00106	0.00384	CcSEcCtD
Lithium—Headache—Vandetanib—thyroid cancer	0.00106	0.00383	CcSEcCtD
Lithium—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00104	0.00376	CcSEcCtD
Lithium—Hypertonia—Epirubicin—thyroid cancer	0.00104	0.00375	CcSEcCtD
Lithium—Nausea—Vandetanib—thyroid cancer	0.00101	0.00363	CcSEcCtD
Lithium—Dyspepsia—Sorafenib—thyroid cancer	0.00101	0.00363	CcSEcCtD
Lithium—Coma—Doxorubicin—thyroid cancer	0.001	0.00361	CcSEcCtD
Lithium—Decreased appetite—Sorafenib—thyroid cancer	0.000994	0.00359	CcSEcCtD
Lithium—Fatigue—Sorafenib—thyroid cancer	0.000986	0.00356	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—thyroid cancer	0.00096	0.00347	CcSEcCtD
Lithium—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000935	0.00337	CcSEcCtD
Lithium—Abdominal pain—Sorafenib—thyroid cancer	0.000904	0.00326	CcSEcCtD
Lithium—Body temperature increased—Sorafenib—thyroid cancer	0.000904	0.00326	CcSEcCtD
Lithium—Lethargy—Epirubicin—thyroid cancer	0.000877	0.00317	CcSEcCtD
Lithium—Asthenia—Sorafenib—thyroid cancer	0.00082	0.00296	CcSEcCtD
Lithium—Lethargy—Doxorubicin—thyroid cancer	0.000812	0.00293	CcSEcCtD
Lithium—Ataxia—Epirubicin—thyroid cancer	0.000808	0.00292	CcSEcCtD
Lithium—Dehydration—Epirubicin—thyroid cancer	0.000799	0.00289	CcSEcCtD
Lithium—Dry skin—Epirubicin—thyroid cancer	0.000788	0.00284	CcSEcCtD
Lithium—Diarrhoea—Sorafenib—thyroid cancer	0.000782	0.00282	CcSEcCtD
Lithium—Gastritis—Epirubicin—thyroid cancer	0.000761	0.00275	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—thyroid cancer	0.000758	0.00274	CcSEcCtD
Lithium—Dizziness—Sorafenib—thyroid cancer	0.000756	0.00273	CcSEcCtD
Lithium—Ataxia—Doxorubicin—thyroid cancer	0.000748	0.0027	CcSEcCtD
Lithium—Dehydration—Doxorubicin—thyroid cancer	0.00074	0.00267	CcSEcCtD
Lithium—Dry skin—Doxorubicin—thyroid cancer	0.000729	0.00263	CcSEcCtD
Lithium—Vomiting—Sorafenib—thyroid cancer	0.000727	0.00262	CcSEcCtD
Lithium—Rash—Sorafenib—thyroid cancer	0.000721	0.0026	CcSEcCtD
Lithium—Dermatitis—Sorafenib—thyroid cancer	0.00072	0.0026	CcSEcCtD
Lithium—Headache—Sorafenib—thyroid cancer	0.000716	0.00259	CcSEcCtD
Lithium—Gastritis—Doxorubicin—thyroid cancer	0.000704	0.00254	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—thyroid cancer	0.000701	0.00253	CcSEcCtD
Lithium—Nausea—Sorafenib—thyroid cancer	0.000679	0.00245	CcSEcCtD
Lithium—Weight increased—Epirubicin—thyroid cancer	0.000676	0.00244	CcSEcCtD
Lithium—Weight decreased—Epirubicin—thyroid cancer	0.000672	0.00243	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—thyroid cancer	0.00067	0.00242	CcSEcCtD
Lithium—Drowsiness—Epirubicin—thyroid cancer	0.000662	0.00239	CcSEcCtD
Lithium—Weight increased—Doxorubicin—thyroid cancer	0.000626	0.00226	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—thyroid cancer	0.000622	0.00225	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00062	0.00224	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—thyroid cancer	0.000613	0.00221	CcSEcCtD
Lithium—Bradycardia—Epirubicin—thyroid cancer	0.000605	0.00219	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—thyroid cancer	0.00056	0.00202	CcSEcCtD
Lithium—Tinnitus—Epirubicin—thyroid cancer	0.000554	0.002	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—thyroid cancer	0.000531	0.00192	CcSEcCtD
Lithium—Alopecia—Epirubicin—thyroid cancer	0.000525	0.0019	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—thyroid cancer	0.000513	0.00185	CcSEcCtD
Lithium—Flatulence—Epirubicin—thyroid cancer	0.00051	0.00184	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—thyroid cancer	0.000507	0.00183	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—thyroid cancer	0.000492	0.00177	CcSEcCtD
Lithium—Vision blurred—Epirubicin—thyroid cancer	0.000488	0.00176	CcSEcCtD
Lithium—Alopecia—Doxorubicin—thyroid cancer	0.000486	0.00176	CcSEcCtD
Lithium—Agitation—Epirubicin—thyroid cancer	0.000476	0.00172	CcSEcCtD
Lithium—Flatulence—Doxorubicin—thyroid cancer	0.000472	0.0017	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—thyroid cancer	0.000469	0.00169	CcSEcCtD
Lithium—Vertigo—Epirubicin—thyroid cancer	0.000465	0.00168	CcSEcCtD
Lithium—Syncope—Epirubicin—thyroid cancer	0.000464	0.00168	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—thyroid cancer	0.000455	0.00164	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—thyroid cancer	0.000451	0.00163	CcSEcCtD
Lithium—Convulsion—Epirubicin—thyroid cancer	0.000448	0.00162	CcSEcCtD
Lithium—Arthralgia—Epirubicin—thyroid cancer	0.000441	0.00159	CcSEcCtD
Lithium—Agitation—Doxorubicin—thyroid cancer	0.00044	0.00159	CcSEcCtD
Lithium—Discomfort—Epirubicin—thyroid cancer	0.000435	0.00157	CcSEcCtD
Lithium—Dry mouth—Epirubicin—thyroid cancer	0.000431	0.00156	CcSEcCtD
Lithium—Vertigo—Doxorubicin—thyroid cancer	0.00043	0.00155	CcSEcCtD
Lithium—Syncope—Doxorubicin—thyroid cancer	0.00043	0.00155	CcSEcCtD
Lithium—Confusional state—Epirubicin—thyroid cancer	0.000426	0.00154	CcSEcCtD
Lithium—Oedema—Epirubicin—thyroid cancer	0.000422	0.00153	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—thyroid cancer	0.000421	0.00152	CcSEcCtD
Lithium—Shock—Epirubicin—thyroid cancer	0.000416	0.0015	CcSEcCtD
Lithium—Convulsion—Doxorubicin—thyroid cancer	0.000415	0.0015	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—thyroid cancer	0.000408	0.00147	CcSEcCtD
Lithium—Discomfort—Doxorubicin—thyroid cancer	0.000403	0.00145	CcSEcCtD
Lithium—Anorexia—Epirubicin—thyroid cancer	0.000403	0.00145	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—thyroid cancer	0.000399	0.00144	CcSEcCtD
Lithium—Hypotension—Epirubicin—thyroid cancer	0.000395	0.00143	CcSEcCtD
Lithium—Confusional state—Doxorubicin—thyroid cancer	0.000394	0.00142	CcSEcCtD
Lithium—Oedema—Doxorubicin—thyroid cancer	0.000391	0.00141	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000385	0.00139	CcSEcCtD
Lithium—Shock—Doxorubicin—thyroid cancer	0.000385	0.00139	CcSEcCtD
Lithium—Somnolence—Epirubicin—thyroid cancer	0.000376	0.00136	CcSEcCtD
Lithium—Anorexia—Doxorubicin—thyroid cancer	0.000373	0.00135	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—thyroid cancer	0.000372	0.00134	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—thyroid cancer	0.000367	0.00133	CcSEcCtD
Lithium—Hypotension—Doxorubicin—thyroid cancer	0.000365	0.00132	CcSEcCtD
Lithium—Fatigue—Epirubicin—thyroid cancer	0.000364	0.00131	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000356	0.00129	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—thyroid cancer	0.000348	0.00126	CcSEcCtD
Lithium—Somnolence—Doxorubicin—thyroid cancer	0.000348	0.00125	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000345	0.00125	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—thyroid cancer	0.000344	0.00124	CcSEcCtD
Lithium—GSK3A—B Cell Activation—KRAS—thyroid cancer	0.000342	0.000635	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—NRAS—thyroid cancer	0.000341	0.000633	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—HRAS—thyroid cancer	0.000341	0.000633	CbGpPWpGaD
Lithium—Decreased appetite—Doxorubicin—thyroid cancer	0.00034	0.00123	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—NRAS—thyroid cancer	0.000339	0.000629	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—HRAS—thyroid cancer	0.000339	0.000629	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—NRAS—thyroid cancer	0.000338	0.000626	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—HRAS—thyroid cancer	0.000338	0.000626	CbGpPWpGaD
Lithium—Fatigue—Doxorubicin—thyroid cancer	0.000337	0.00122	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—PTEN—thyroid cancer	0.000337	0.000624	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—HRAS—thyroid cancer	0.000336	0.000623	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—HRAS—thyroid cancer	0.000334	0.00062	CbGpPWpGaD
Lithium—Body temperature increased—Epirubicin—thyroid cancer	0.000334	0.00121	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—thyroid cancer	0.000334	0.00121	CcSEcCtD
Lithium—GSK3A—Signaling by SCF-KIT—AKT1—thyroid cancer	0.000333	0.000618	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NRAS—thyroid cancer	0.000333	0.000617	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—AKT1—thyroid cancer	0.000332	0.000616	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IFNA2—thyroid cancer	0.000331	0.000614	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PTEN—thyroid cancer	0.00033	0.000611	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	0.00033	0.000611	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—AKT1—thyroid cancer	0.000329	0.000611	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PTEN—thyroid cancer	0.000328	0.000609	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KRAS—thyroid cancer	0.000328	0.000608	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.000328	0.000608	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PPARG—thyroid cancer	0.000327	0.000606	CbGpPWpGaD
Lithium—Feeling abnormal—Doxorubicin—thyroid cancer	0.000322	0.00116	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—PTEN—thyroid cancer	0.000322	0.000597	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—AKT1—thyroid cancer	0.000322	0.000596	CbGpPWpGaD
Lithium—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00032	0.00115	CcSEcCtD
Lithium—GSK3B—GAB1 signalosome—AKT1—thyroid cancer	0.000319	0.000592	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—AKT1—thyroid cancer	0.000319	0.000591	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	0.000318	0.000589	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—NRAS—thyroid cancer	0.000318	0.000589	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—NRAS—thyroid cancer	0.000318	0.000589	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	0.000315	0.000585	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000315	0.000585	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—NRAS—thyroid cancer	0.000315	0.000584	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	0.000315	0.000583	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—HRAS—thyroid cancer	0.000315	0.000583	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—HRAS—thyroid cancer	0.000315	0.000583	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KRAS—thyroid cancer	0.000314	0.000582	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—AKT1—thyroid cancer	0.000314	0.000582	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—NRAS—thyroid cancer	0.000312	0.000579	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—HRAS—thyroid cancer	0.000312	0.000578	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thyroid cancer	0.000312	0.000578	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—NRAS—thyroid cancer	0.000311	0.000576	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000309	0.000574	CbGpPWpGaD
Lithium—Abdominal pain—Doxorubicin—thyroid cancer	0.000309	0.00112	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—thyroid cancer	0.000309	0.00112	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR in Cancer—HRAS—thyroid cancer	0.000309	0.000573	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KRAS—thyroid cancer	0.000309	0.000573	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—HRAS—thyroid cancer	0.000308	0.000571	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—HRAS—thyroid cancer	0.000305	0.000566	CbGpPWpGaD
Lithium—Asthenia—Epirubicin—thyroid cancer	0.000303	0.00109	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—AKT1—thyroid cancer	0.000302	0.000561	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—AKT1—thyroid cancer	0.000301	0.000558	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—AKT1—thyroid cancer	0.0003	0.000556	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—AKT1—thyroid cancer	0.000298	0.000553	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—AKT1—thyroid cancer	0.000297	0.00055	CbGpPWpGaD
Lithium—GSK3B—Immune System—TPR—thyroid cancer	0.000296	0.000549	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—AKT1—thyroid cancer	0.000295	0.000548	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KRAS—thyroid cancer	0.000295	0.000547	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NRAS—thyroid cancer	0.000294	0.000545	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KRAS—thyroid cancer	0.000294	0.000544	CbGpPWpGaD
Lithium—GSK3B—Immune System—LGALS3—thyroid cancer	0.000293	0.000544	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NRAS—thyroid cancer	0.000293	0.000543	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KRAS—thyroid cancer	0.000292	0.000542	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—thyroid cancer	0.000291	0.00054	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRKAR1A—thyroid cancer	0.000291	0.00054	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	0.000291	0.00054	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KRAS—thyroid cancer	0.000291	0.000539	CbGpPWpGaD
Lithium—Diarrhoea—Epirubicin—thyroid cancer	0.000289	0.00104	CcSEcCtD
Lithium—IMPA2—Metabolism—PTGS2—thyroid cancer	0.000288	0.000535	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	0.000286	0.000531	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	0.000281	0.000522	CbGpPWpGaD
Lithium—Asthenia—Doxorubicin—thyroid cancer	0.00028	0.00101	CcSEcCtD
Lithium—Dizziness—Epirubicin—thyroid cancer	0.000279	0.00101	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—thyroid cancer	0.000279	0.000517	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	0.000279	0.000517	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—AKT1—thyroid cancer	0.000278	0.000515	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	0.000278	0.000515	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—AKT1—thyroid cancer	0.000278	0.000515	CbGpPWpGaD
Lithium—GSK3A—Disease—CALCA—thyroid cancer	0.000277	0.000513	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRG1—thyroid cancer	0.000276	0.000512	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—AKT1—thyroid cancer	0.000275	0.000511	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—HRAS—thyroid cancer	0.000274	0.000509	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	0.000273	0.000507	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—thyroid cancer	0.000273	0.000507	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—thyroid cancer	0.000273	0.000507	CbGpPWpGaD
Lithium—GSK3B—Disease—TPR—thyroid cancer	0.000273	0.000507	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—AKT1—thyroid cancer	0.000273	0.000506	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—AKT1—thyroid cancer	0.000272	0.000504	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDK1—thyroid cancer	0.000271	0.000503	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KRAS—thyroid cancer	0.000271	0.000503	CbGpPWpGaD
Lithium—GSK3B—Disease—PRKAR1A—thyroid cancer	0.000269	0.000498	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—thyroid cancer	0.000269	0.000498	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—thyroid cancer	0.000269	0.00097	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—thyroid cancer	0.000267	0.000966	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—KRAS—thyroid cancer	0.000267	0.000496	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—thyroid cancer	0.000267	0.000495	CbGpPWpGaD
Lithium—Rash—Epirubicin—thyroid cancer	0.000266	0.000962	CcSEcCtD
Lithium—Dermatitis—Epirubicin—thyroid cancer	0.000266	0.000961	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—NRG1—thyroid cancer	0.000265	0.000492	CbGpPWpGaD
Lithium—Headache—Epirubicin—thyroid cancer	0.000265	0.000955	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—HRAS—thyroid cancer	0.000263	0.000487	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000261	0.000485	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TCF7L1—thyroid cancer	0.000261	0.000485	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNA2—thyroid cancer	0.000261	0.000484	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSHR—thyroid cancer	0.000259	0.00048	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—thyroid cancer	0.000258	0.000933	CcSEcCtD
Lithium—GSK3A—B Cell Activation—AKT1—thyroid cancer	0.000257	0.000477	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—thyroid cancer	0.000257	0.000476	CbGpPWpGaD
Lithium—GSK3B—Disease—MEN1—thyroid cancer	0.000257	0.000476	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000255	0.000472	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KRAS—thyroid cancer	0.000253	0.000469	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—thyroid cancer	0.000252	0.000468	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—thyroid cancer	0.000252	0.000467	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTEN—thyroid cancer	0.000251	0.000466	CbGpPWpGaD
Lithium—Nausea—Epirubicin—thyroid cancer	0.000251	0.000906	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—HRAS—thyroid cancer	0.000251	0.000465	CbGpPWpGaD
Lithium—GSK3A—Disease—CDK1—thyroid cancer	0.00025	0.000465	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—thyroid cancer	0.00025	0.000463	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—thyroid cancer	0.000249	0.000897	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—HRAS—thyroid cancer	0.000248	0.000461	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—thyroid cancer	0.000247	0.000458	CbGpPWpGaD
Lithium—Rash—Doxorubicin—thyroid cancer	0.000246	0.00089	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—thyroid cancer	0.000246	0.000889	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—thyroid cancer	0.000246	0.000457	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000246	0.000456	CbGpPWpGaD
Lithium—Headache—Doxorubicin—thyroid cancer	0.000245	0.000884	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	0.000244	0.000452	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MEN1—thyroid cancer	0.000243	0.000451	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PTEN—thyroid cancer	0.000243	0.00045	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.000242	0.000449	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—thyroid cancer	0.000242	0.000449	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—thyroid cancer	0.000236	0.000437	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	0.000232	0.000431	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—thyroid cancer	0.000232	0.000431	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—thyroid cancer	0.000232	0.000431	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—thyroid cancer	0.000232	0.000838	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—AKT1—thyroid cancer	0.000232	0.00043	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—thyroid cancer	0.00023	0.000427	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PPARG—thyroid cancer	0.000228	0.000424	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—thyroid cancer	0.000228	0.000423	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—thyroid cancer	0.000227	0.000422	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTEN—thyroid cancer	0.000224	0.000415	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—thyroid cancer	0.000223	0.000413	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—thyroid cancer	0.000221	0.000411	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—thyroid cancer	0.00022	0.000409	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTCH1—thyroid cancer	0.00022	0.000408	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—thyroid cancer	0.00022	0.000407	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—thyroid cancer	0.00022	0.000407	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—thyroid cancer	0.000219	0.000407	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—thyroid cancer	0.000218	0.000405	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRG1—thyroid cancer	0.000218	0.000404	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—thyroid cancer	0.000216	0.000401	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—thyroid cancer	0.000215	0.000399	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	0.000215	0.000399	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—thyroid cancer	0.000214	0.000397	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	0.000206	0.000382	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—thyroid cancer	0.000205	0.000381	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—thyroid cancer	0.000205	0.000381	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	0.000205	0.000381	CbGpPWpGaD
Lithium—GSK3B—Disease—CALCA—thyroid cancer	0.000204	0.000379	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—thyroid cancer	0.000203	0.000377	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—thyroid cancer	0.000202	0.000374	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SST—thyroid cancer	0.000201	0.000373	CbGpPWpGaD
Lithium—GSK3A—Disease—NRG1—thyroid cancer	0.000201	0.000373	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—thyroid cancer	0.000201	0.000372	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDK1—thyroid cancer	0.0002	0.000372	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—thyroid cancer	0.000196	0.000363	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—thyroid cancer	0.000194	0.00036	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CALCA—thyroid cancer	0.000194	0.000359	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNA2—thyroid cancer	0.000193	0.000358	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSHR—thyroid cancer	0.000191	0.000355	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—thyroid cancer	0.00019	0.000352	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—thyroid cancer	0.000189	0.000351	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000188	0.000349	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—thyroid cancer	0.000187	0.000347	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—thyroid cancer	0.000186	0.000346	CbGpPWpGaD
Lithium—GSK3B—Disease—CDK1—thyroid cancer	0.000185	0.000343	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000182	0.000337	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—thyroid cancer	0.000181	0.000335	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MEN1—thyroid cancer	0.00018	0.000334	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—thyroid cancer	0.00018	0.000334	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—thyroid cancer	0.000177	0.000327	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDK1—thyroid cancer	0.000175	0.000325	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—thyroid cancer	0.000174	0.000322	CbGpPWpGaD
Lithium—GSK3A—Disease—HIF1A—thyroid cancer	0.000173	0.00032	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—thyroid cancer	0.000169	0.000313	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thyroid cancer	0.000168	0.000312	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—thyroid cancer	0.000167	0.00031	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH1—thyroid cancer	0.000163	0.000302	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRG1—thyroid cancer	0.000161	0.000298	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—thyroid cancer	0.00016	0.000298	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—thyroid cancer	0.000158	0.000294	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—thyroid cancer	0.000156	0.00029	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SST—thyroid cancer	0.000149	0.000276	CbGpPWpGaD
Lithium—GSK3B—Disease—NRG1—thyroid cancer	0.000149	0.000276	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—thyroid cancer	0.000145	0.000269	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—thyroid cancer	0.000144	0.000267	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—thyroid cancer	0.000143	0.000266	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CALCA—thyroid cancer	0.000143	0.000266	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—thyroid cancer	0.000143	0.000265	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRG1—thyroid cancer	0.000141	0.000261	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—thyroid cancer	0.00014	0.000259	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—thyroid cancer	0.00014	0.000259	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—thyroid cancer	0.000138	0.000257	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—thyroid cancer	0.000138	0.000256	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—thyroid cancer	0.000133	0.000247	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—thyroid cancer	0.000133	0.000246	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDK1—thyroid cancer	0.00013	0.00024	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—thyroid cancer	0.000129	0.000239	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—thyroid cancer	0.000129	0.000239	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—thyroid cancer	0.000128	0.000237	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—thyroid cancer	0.000126	0.000234	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—thyroid cancer	0.000123	0.000229	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—thyroid cancer	0.000122	0.000227	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—thyroid cancer	0.000121	0.000224	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—thyroid cancer	0.00012	0.000223	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—thyroid cancer	0.000119	0.00022	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—thyroid cancer	0.000117	0.000218	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—thyroid cancer	0.000115	0.000214	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—thyroid cancer	0.000109	0.000202	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—thyroid cancer	0.000108	0.0002	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—thyroid cancer	0.000106	0.000197	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—thyroid cancer	0.000106	0.000196	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRG1—thyroid cancer	0.000104	0.000193	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—thyroid cancer	0.000104	0.000192	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—thyroid cancer	0.000102	0.00019	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—thyroid cancer	0.000102	0.000189	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—thyroid cancer	0.000101	0.000187	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—thyroid cancer	0.0001	0.000186	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—thyroid cancer	9.73e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—thyroid cancer	9.34e-05	0.000173	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—thyroid cancer	9.03e-05	0.000168	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—thyroid cancer	9.03e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—thyroid cancer	8.98e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—thyroid cancer	8.93e-05	0.000166	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—thyroid cancer	8.67e-05	0.000161	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—thyroid cancer	8.53e-05	0.000158	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—thyroid cancer	8.37e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—thyroid cancer	8.06e-05	0.000149	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—thyroid cancer	7.97e-05	0.000148	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—thyroid cancer	7.73e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—thyroid cancer	7.66e-05	0.000142	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—thyroid cancer	7.44e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—thyroid cancer	7.4e-05	0.000137	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—thyroid cancer	7.31e-05	0.000136	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—thyroid cancer	7.19e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—thyroid cancer	7.12e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—thyroid cancer	7.05e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—thyroid cancer	6.64e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—thyroid cancer	6.57e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—thyroid cancer	6.29e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—thyroid cancer	6.29e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—thyroid cancer	6.19e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—thyroid cancer	5.8e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—thyroid cancer	5.71e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—thyroid cancer	5.41e-05	0.0001	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—thyroid cancer	5.4e-05	0.0001	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—thyroid cancer	5.26e-05	9.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—thyroid cancer	5.21e-05	9.66e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—thyroid cancer	4.86e-05	9.01e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—thyroid cancer	4.81e-05	8.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—thyroid cancer	4.65e-05	8.62e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—thyroid cancer	4.64e-05	8.61e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—thyroid cancer	4.6e-05	8.54e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—thyroid cancer	4.29e-05	7.95e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—thyroid cancer	4.06e-05	7.54e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—thyroid cancer	4e-05	7.42e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—thyroid cancer	3.56e-05	6.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—thyroid cancer	3.4e-05	6.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—thyroid cancer	3e-05	5.57e-05	CbGpPWpGaD
